These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins]. Pavese P; Brion JP; Meusnier T; Stahl JP Ann Med Interne (Paris); 1997; 148(3):287-8. PubMed ID: 9255342 [No Abstract] [Full Text] [Related]
32. Starch microparticles as an adjuvant in immunisation: effect of route of administration on the immune response in mice. Stertman L; Strindelius L; Sjöholm I Vaccine; 2004 Jul; 22(21-22):2863-72. PubMed ID: 15246622 [TBL] [Abstract][Full Text] [Related]
33. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Gordon DJ; Sloan SR; de Jong JL Am J Hematol; 2009 Nov; 84(11):771-2. PubMed ID: 19806664 [No Abstract] [Full Text] [Related]
34. Experience with sandoglobulin in bone marrow transplantation. Tutschka PJ; Copelan EA Int J Cell Cloning; 1986; 4 Suppl 1():181-8. PubMed ID: 3018102 [No Abstract] [Full Text] [Related]
35. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin. Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785 [TBL] [Abstract][Full Text] [Related]
36. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. Norrby-Teglund A; Haque KN; Hammarström L J Intern Med; 2006 Dec; 260(6):509-16. PubMed ID: 17116001 [TBL] [Abstract][Full Text] [Related]
37. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease. Khan S; Doré PC; Sewell WA Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907 [No Abstract] [Full Text] [Related]
38. [Stimulation of the nonspecific resistance by beta-heptylglycoside-muramyldipeptide in mice]. Kaliuzhin OV; Kaliuzhin VV; Zemliakov AE; Elkina SI; Shkalev MV; Sergeev VV Biull Eksp Biol Med; 1999 May; 127(5):543-5. PubMed ID: 10399577 [No Abstract] [Full Text] [Related]
39. Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation. Chensue SW; Warmington KS; Allenspach EJ; Lu B; Gerard C; Kunkel SL; Lukacs NW J Immunol; 1999 Jul; 163(1):165-73. PubMed ID: 10384113 [TBL] [Abstract][Full Text] [Related]
40. Thymopentin in the treatment of alopecia areata. Orecchia G Dermatologica; 1989; 178(4):231. PubMed ID: 2670621 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]